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Abstract
Direct-acting fibrin(ogen)olytic agents such as plasmin have been proved to contain effective and safety thrombolytic
potential. Unfortunately, plasmin is ineffective when administered by the intravenous route because it was neutralized by
plasma antiplasmin. Direct-acting fibrin(ogen)olytic agents with resistance against antiplasmin will brighten the prospect of
anti-thrombosis. As reported in ‘Compendium of Materia Medica’, the insect of Eupolyphaga sinensis Walker has been used
as traditional anti-thrombosis medicine without bleeding risk for several hundreds years. Currently, we have identified a
fibrin(ogen)olytic protein (Eupolytin1) containing both fibrin(ogen)olytic and plasminogen-activating (PA) activities from the
beetle, E. sinensis. Objectives: To investigate the role of native and recombinant eupolytin1 in fibrin(ogen)olytic and
plasminogen-activating processes. Methods and Results: Using thrombus animal model, eupolytin1 was proved to contain
strong and rapid thrombolytic ability and safety in vivo, which are better than that of urokinase. Most importantly, no
bleeding complications were appeared even the intravenous dose up to 0.12 mmol/kg body weight (3 times of tested dose
which could completely lyse experimental thrombi) in rabbits. It is the first report of thrombolytic agents containing both
direct-acting fibrin(ogen)olytic and plasminogen-activating activities. Conclusions: The study identified novel thrombolytic
agent with prospecting clinical potential because of its bi-functional merits containing both plasmin- and PA-like activities
and unique pharmacological kinetics in vivo.
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Introduction
The incidence of thrombotic disorders including cerebral stroke,
myocardial infarction, and venous thromboembolism are rapidly
increasing throughout the world. Thrombolytic therapy is an
acknowledged approach to treat these disorders. All thrombolytic
agents in current clinical usage are plasminogen activators (PA)
which require plasminogen to achieve thrombosis. Although
effective, PAs uniformly increase the risk of bleeding complica-
tions, especially intracranial hemorrhage, and no laboratory test is
applicable to avoid such bleeding [1]. This issue arouses the
attempt to identify improved regents that would avoid hemorrhage
complications and increase thrombolytic potential. Plasmin is a
‘‘direct-acting’’ thrombolytic agent that had been considered to
contain greater thrombolytic efficacy and safety than can be
afforded by PAs. Although plasmin is direct fibrinolytic enzyme
without requirement of plasminogen, it is ineffective when
administered by the intravenous route because it was neutralized
by plasma antiplasmin [1–3].
Some anti-thrombosis components including thrombin inhibi-
tors, platelet aggregation inhibitors, vasodilators, fibrin(ogen)olytic
enzymes, apyrases and peroxidases have been identified from
some medicinal insects [4–11]. Recently, 12 fibrin(ogen)olytic
enzymes have been found in the salivary glands of the horsefly,
Tabanus yao Macquart [8,9], suggesting that some medical insects
contain diverse direct-acting thrombolytic agents. In oriental
regions, a number of traditional treatment regimens have been
used for thrombotic diseases and many of these crude drugs have
been evaluated through the purification and characterization of
the active substances from insects [8–13]. The ground beetle of E.
sinensis has been used in East Asia as crude drugs for thrombolytic
therapy and is presently reared as a medicinal insect in China.
Recently, fibrinolytic activities have been found in this insect but
the component was not characterized [14]. In order to identify
and characterize the interesting thrombolytic compounds and help
in identifying novel thrombolytic candidates, we investigate
thrombolytic molecules in the insect of E. sinensis in the current
work.
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Identification of anatomical position in the ground beetle
with fibrinogenolytic activity
As illustrated in Fig. 1A, all the test tissues or organs (Legs,
integuments, fat bodies, heads, digestive tracts and hemolymph) in
E. sinensis had fibrinogenolytic ability. Compared with other tissues
or organs containing activity to only hydrolyze a-chain of
fibrinogen, digestive tracts of E. sinensis can hydrolyze a-, b-, and
l-chains of fibrinogen. Further analysis indicated that mid-gut
could hydrolyze a-, b-, and l-chains of fibrinogen while fore-gut
and hind-gut only hydrolyzed a- and b-chains (Fig. 1B).
Purification of fibriongenolytic molecules from mid-guts
of the beetle
As indicated in Fig. 1C, four protein peaks were eluted from the
supernatant of the beetle mid-gut extracts by CM-Sephadex C-25
cationic exchange column. The first peak showed fibrinogenolytic
activity and subjected further fractionation by Sephadex G-75 gel
filtration (Fig. 1D). The pooled fractions indicated by an arrow in
Fig. 1D contained fibrinogenolytic activity was applied to an
anionic exchange FPLC column of Resource Q and more than ten
protein peaks were eluted out (Fig. 1E). The fibrinogenolytic
activity was concentrated on the eluted peak indicated by an arrow
in Fig. 1E. The final purification of fibrinogenolytic molecule was
performed by an anionic exchange FPLC column of Mono Q
(Fig. 1F). A fibrinogenolytic protein named eupolytin1 (indicated
by an arrow in Fig. 1F) was purified form the last step. The SDS-
PAGE analysis indicated that it is homogenates with molecular
weight of 26 kDa (inset in Fig. 1F).
Identification and characterization of eupolytin1
A purified fibrinogenolytic protein (eupolytin1) was subjected to
amino acid sequence analysis by Edman degradation. The amino
acid sequence of the amino-terminal and partial interior amino
acid fragments recovered from the trypsin hydrolysis are illustrated
in Fig. 2. Based on the amino acid sequences of the N-terminus,
degenerated primers were designed to screen the cDNA clones
with sequences encoding eupolytin1. The complete cDNA
sequences encoding eupolytin1 was cloned from the mit-gut
cDNA library of the beetle (GenBank accession Gu187070). The
cDNA encodes the proprotein composed of 254 amino acid (aa)
residues including predicted signal peptides (27 aa) and mature
eupolytin1 (Fig. 2). By BLAST search, it shows 40–50% identity
with insect serine proteases. Three conserved amino acid residues
(His69, Asp114 and Ser208) are predicted to form catalytic triad
for serine proteases. The insect serine protease multi-sequence
alignments were performed on basis of the whole sequence of
precursor. The condensed multifurcating tree was constructed
emphasizing the reliable portion of pattern branches (Fig. 3).
Fibrinogenolytic activities and effect factors
Native and recombinant eupolytin1 (1 mg) were incubated with
20 mg fibrinogen in 20 ml ABS at 37uC for 1 h and subjected to
SDS-PAGE analysis, respectively (Fig. 4A). They showed strong
fibrinogenolytic activities. Eupolytin1 could hydrolyze three chains
(a, b and l) of fibrinogen. The effects of metal ions, PMSF and
EDTA on eupolytin1 were illustrated in Fig. 4B–C. Ca
2+ and Mg
2+
had little effect on fibrinogenolytic activity of eupolytin1. Zn
2+ and
Cu
2+ appeared to have a little inhibition on fibrinogenolytic activity
of eupolytin1. PMSF could significantly inhibit the activity of
eupolytin1. EDTA had no effect on eupolytin1 (Data not shown).
The result of anti-plasmin-interference experiment was displayed in
Fig. 4D. It was observed that the fibrinogen was still hydrolyzed by
eupolytin1 with the presence of aprotinin, suggesting that
eupolytin1 may exert the fibrin(ogen)olytic activity directly in
addition to its plasminogen-activating activity. Fig. 5A and B
showed that eupolytin1 hydrolyzed fibrinogen in dose- and time-
dependent manners. Eupolytin1 only took 1.5 h to completely
hydrolyze 8 mg human whole clot with serum while it took 18 h to
completely hydrolyze the clot without serum (Fig. 5C), suggesting
that eupolytin1 has an ability to activate plasminogen present in the
serum. Kinetic parameters of native and recombinant eupolytin1
for different chromogenic substrates were listed in table 1. They
could hydrolyze substrates of T6140 and B3133. T6140 is the
special substratefor plasmin whileB3133is thesubstrate fortyrpsin-
like serine proteases. The current results indicated that eupolytin1
had activities of plasmin- and tyrpsin-like serine proteases.
Plasminogen activation by eupolytin1
Using human urokinase as a positive control, eupolytin1’s ability
to activate human plasminogen was assayed. Eupolytin1 could
activate plasminogen as illustrated in Fig. 6. In the absence of
plasminogen, eupolytin1 could hydrolyze fibrin (Fig. 6B); in the
presence of plasminogen, its ability to hydrolyze fibrin was
increased (Fig. 6A and C). This result indicated that eupolytin1 not
only directly hydrolyzed fibrin but also activated plasminogen to
hydrolyze fibrin. To the best of our knowledge, this is the first
report of the bi-functional proteins containing both fibrinolysis and
plasminogen-activation functions.
In vivo anti-thrombosis activity
As illustrated in Fig. 7A, an average weight of 3.760.3 mg
thrombi were formed in the nylon strings after 5 min of perfusion
in the control (saline) arteriovenous shunt rat models. Adminis-
tration of eupolytin1 and urokinase obviously reduced thrombus
weight in a dose-dependent manner. The thrombus weight was
reduced to 160.2 mg by eupolytin1 administration of 0.06 mmol/
kg. At the same dose of urokinase, the thrombus weight was
reduced to 1.760.3 mg. Thrombosis induced by carrageenin in
mice tail could also significantly inhibited by eupolytin1 and
urokinase in a dose-dependent manner as illustrated in Fig. 7B.
0.01–0.06-mmol dosage of eupolytin1 could completely scavenge
the induced thrombus after 48 h treatment. In all the tested
dosages, the anti-thrombosis ability of eupolytin1 was much better
than that of urokinase.
Hemostatic safety
Five animals that were administered with saline control showed
no change in PBT (2.560.7 min). All the tested dosages of
eupolytin1 had no significant effects on the PBT. At dosages of
0.08 and 0.12 mmol/kg body weight, urokinase strikingly pro-
longed the PBT (Table 1). Fig. 8A and B showed the absolute total
duration of bleeding for each experimental rabbit. Bleeding for
more than 50 minutes occurred at all rabbits receiving urokinase
treatment of 0.08 and 0.12 mmol/kg. One of five rabbits receiving
urokinase treatment of 0.04 mmol/kg also had total bleeding for
more than 50 min. Most of them were more than 150 min; one of
them was up to 360 min. Two of five, three of five rabbits
receiving eupolytin treatment of 0.08 and 0.12 mmol/kg, respec-
tively, have been found bleeding for more than 50 min but always
less than 100 min (Fig. 8A and B). ELISA was used to assess
kinetics of fibrinogen level in animal plasma. As illustrated in
Fig. 8C, 0.08 mmol-dosage urokinase progressively decreased the
concentration of fibrinogen in plasma, and such decline was not
stopped yet even after 24 h treatment (Data not shown). A
0.08 m mol-dosage eupolytin1 also progressively decreased the
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PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17519Figure 1. Purification of fibriongenolytic molecules from mid-guts of E. sinensis. and B: tissues extrats from legs, integuments, fat bodies,
heads, digestive tracts and hemolymph of E. sinensis were used to test their thrombolytic abilities against fibrinogen. 5 mg total extracted protein was
incubated with 20 mg fibrinogen for 10 h at 37uC and subjected reduced SDS-PAGE analysis in a gel concentration of 15%. C: cationic exchange
chromatography of aliquot of 1.0 g MGS by CM-Sephadex C-25 (Amersham Biosciences, 2.6640 cm). The interesting peak was indicated by an arrow.
D: the collected fraction containing fibrinogenolytic activity from ‘‘C’’ was subjected to Sephadex G-75 gel filtration (Amersham Biosciences,
superfine, 2.66100 cm), the elution was performed by 0.1 M Tris-HCl pH 7.8 with a flow rate of 0.3 ml/min. E: The collected fraction from ‘‘D’’ was
subjected to AKTA FPLC Resource Q (1 ml volume, Amersham Biosciences) anionic exchange equilibrated with 0.02 M Tris-HCl pH 7.8. The elution
was performed at a flow rate of 1 ml/min with the indicated NaCl gradient. F: the collected fraction from ‘‘E’’ was subjected to AKTA FPLC Mono Q
(1 ml volume, Amersham Biosciences) anionic exchange equilibrated with 0.02 M Tris-HCl pH 8.3. The elution was performed at a flow rate of 1 ml/
min with the indicated NaCl gradient. The purified protein containing fibrinogenolytic activity was indicated by an arrow. Inset in Fig. 1F: SDS-PAGE
analysis of purified protein as indicated in Fig. 1F in 15% gel concentration. R: reduced; UR: Unreduced.
doi:10.1371/journal.pone.0017519.g001
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  A concentration of fibrinogen in plasma, but this stepwise decrease
only lasted 8 h. Afterwards, the plasma fibrinogen concentration
gradually went back to normal level (Fig. 8C).
Discussion
All of the thrombolytics in current clinical use are PAs. One side
they have efficacy to dissolve the thrombi, but the other side they
may potentially cause the bleeding complications [1]. Lots of
efforts have been paid to discover the new thrombolytic agents to
improve efficacy of thrombosis but avoid bleeding risk meanwhile.
In addition, some position such as cerebrosoinal fluid (CSF)
contain little plasminogen, being 1/10 compared with that in the
blood [15–17]. The lower the concentration of plasminogen
surrounding a clot results in the lower the rate of clot lysis. A novel
class of thrombolytics, namely, ‘‘direct-acting’’ agents, which have
ability to directly dissolve thrombi and need no activation of
plasminogen, was considered to have ability for achieving safe
thrombolytic therapy. One of ‘‘direct-acting’’ agents is plasmin.
However, plasma inhibitor neutralizes intravenously-administered
plasmin [1–3]. Exogenous ‘‘direct-acting’’ agents containing
resistance against plasma inhibitor may be excellent thrombolytic
candidates.
A thrombolytic protein (Eupolytin1) was purified and character-
ized from mid-guts of the medicinal insect of E. sinensi. Native
eupolytin1 is composed of 227 aa. BLAST search revealed that it is
a novel protein belonging to serine protease family. Native and
recombinant eupolytin1 could hydrolyze chromogenic substrates
T6140 and B3133 (Table 1), indicating that eupolytin1 contains
plasmin- and trypsin-like activities. Similar to plasmin, eupolytin1
Figure 2. Amino acid sequences of eupolytin1 and its cDNA sequence. The predicted signal peptide is italic. Amino sequences determined
by Edman degradation were underlined.
doi:10.1371/journal.pone.0017519.g002
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recombinant eupolytin1 showed strong fibrino(gen)olytic activities;
20 mg fibrinogen could be completely hydrolyzed by 1 mg
eupolytin1 during 1.5 h (Fig. 4 and 5). Different from known
fibrino(gen)olytic enzymes which onlyhydrolyze a- or/and b-chains
of fibrinogen [8,9], eupolytin1 could hydrolyze a-, b-, and c-chains
of fibrinogen. The current fibrino(gen)olytic enzyme combined with
its strong fibrino(gen)olytic activity revealed the anti-thrombosis
mechanism of the traditional medicinal insect, E. sinensi.
As mentioned above, eupolytin1 had ability to activate human
plasminogen as tPA or uPA did. Fig. 4–6 showed that in addition
to directly hydrolyzing fibrin(ogen) (direct-acting) (Fig. 4, Fig. 5,
Fig. 6B), eupolytin1 could activate plasminogen to hydrolyze fibrin
(indirect-acting) (Fig. 6A and C). As illustrated in Fig. 6A and C,
the synergetic action of these two means (direct-acting and
indirect-acting) obviously improved the fibrinolysis efficiency of
eupolytin1. Such type of bi-functional agent containing both
plasmin- and PA-like activities has more advantages than known
anti-thrombosis agents to treat thrombus.
As mentioned above, eupolytin1 not only directly hydrolyzes
thrombus as plasmin does, but also activates intrinsic plasminogen
to exert anti-thrombosis functions as PA dose. Based on the unique
bi-functional characteristic, we assumed that eupolytin1 has
excellent anti-thrombosis ability in vivo and in vitro. The
experiments of in vitro clot lysis with human blood indicated that
the clot lysis rate of eupolytin1 with serum (1. 5 h) is much faster
than that of eupolytin1 without serum (18 h) (Fig. 5C). This result
indicated that eupolytin1 possibly activated plasminogen in the
serum to hydrolyze the blood clot. Using urokinase as a control,
the thrombolytic results in vivo further confirmed that eupolytin1
has excellent anti-thrombosis ability (Fig. 7). In the both in vivo
anti-thrombosis models (arteriovenous shunt rat model and
thrombosis induced by carrageenin in mice tail), eupolytin1
showed much better anti-thrombosis effects than urokinase.
The risk of hemorrhage was evaluated after eupolytin1
administration in rabbit (Table 2, Fig. 8A and B). Compared
with urokinase, eupolytin1 induced little bleeding even the dose up
to 0.12 mmol/kg body weight. This dose was three times of the
tested dose that could completely lyse experimental thrombi in
mice (Fig. 7). In order to reveal the reason to induce little bleeding
by eupolytin1, the fibrinogen concentration change in rabbit
plasma was traced as illustrated in Fig. 8C. Eupolytin1 could
rapidly decrease plasma fibrinogen concentration. The lowest
fibrinogen concentration could be reached after 8 h eupolytin1
administration, and then returned to normal level after 14 h. The
unique kinetics characteristic of plasma fibrinogen concentration
induced by eupolytin1 not only increases its rate of clot lysis but
also decreases its hemorrhage risk.
Figure 3. Phylogenetic analyses of eupolytin 1 and other insect serine proteases on basis of the whole precursor sequences. The
phylogenetic dendrogram was constructed by the neighbor-joining method based on the proportion difference of aligned amino acid sites of the
sequence. Only branches supported by a bootstrap value of at least 50% (expressed as percentage of 500 bootstrap samples supporting the branch
are shown at branching points.
doi:10.1371/journal.pone.0017519.g003
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PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e17519Figure 4. Fibrinogenolytic activity of eupolytin1 and its effects by metal ions and protease inhibitors. A: native and recombinant
eupolytin1 (1 mg) were incubated with 20 mg fibrinogen for 1 h at 37uC and subjected reduced SDS-PAGE analysis in a gel concentration of 15%; B:
1 mg eupolytin1 was incubated with 20 mg fibrinogen for 1 h at 37uC in the presence of 5 mM indicated metal ion and subjected reduced SDS-PAGE
analysis in a gel concentration of 15%; C & D: 1 mg eupolytin1 was incubated with 20 mg fibrinogen for 1 h at 37uC in the presence of PMSF (C) or
aprotinin (D) with indicated concentration and subjected reduced SDS-PAGE analysis in a gel concentration of 15%. NE: native eupolytin1; RE:
recombinant eupolytin1.
doi:10.1371/journal.pone.0017519.g004
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relationship of the thrombolytic reagent and evaluate its possibility
to be used as safe clinical thrombolytics. In addition, eupolytin1
has a possibility to acts as ‘‘direct-acting’’ thrombolytic agents in
some special position such as CSF containing little plasminogen.
Materials and Methods
Insects
Thirty kg E. sinensis (about 75 000, average weight 0. 4 g) was
reared in the laboratory with free accesses to foods (corn, fish and
vegetable) and water. The laboratory temperature is 2362uC. All
the animal experiments are approved by Kunming Institute of
Zoology, Chinese Academy of Sciences.
The determination of anatomical position with
fibrinogenolytic activity
Legs, integuments, fat bodies, heads, digestive tracts and
hemolymph of E. sinensis were dissected and collected, respectively.
These isolated organs or tissues were homogenized in 0.05 M
acetate-acetate sodium buffer solution, pH 5.0 (ABS), and centri-
fuged at 5000 g for 10 min. The supernatants were used to test their
thrombolytic abilities against fibrinogen as described below.
Purification of thrombolytic component from the mid-
guts of E. sinensis
40 g mid-gut collected from ten kg E. sinensis was homogenized
in 500 ml 0.05 M ABS, and centrifuged at 5000 g for 10 min. The
Figure 5. Eupolytin1 hydrolyzed fibrinogen in dose- (A) and time-dependent manners (B). E: eupolytin1.
doi:10.1371/journal.pone.0017519.g005
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salt) and kept at 280uC. Aliquot of 1.0 g MGS (totaling 80
aliquots) dissolved in 10 ml 0.05 M ABS was dialyzed against 3 L
0.05 M ABS for 12 h, and then was applied to a CM-Sephadex C-
25 (Amersham Biosciences, 2.6640 cm) equilibrated with 0.05 M
ABS. The elution was performed at a flow rate of 1 ml/min with
the indicated NaCl gradient in 0.05 M ABS, with fractions
collected every 3.0 ml. The absorbance of the eluate was
monitored at 280 nm (Fig. 1C). Every fraction was subjected to
pharmacological testing including inhibition of platelet aggrega-
tion, serine protease hydrolysis on chromogenic substrates, blood
coagulation and fibrinogenolysis as indicated in the experimental
protocol. Protein peaks containing tested pharmacological activ-
ities were pooled and purified further by Sephadex G-75 gel
filtration, Resource Q and Mono Q anionic exchange fast protein
liquid chromatography (FPLC) columns as illustrated in Fig. 1D–
F. All the purified interesting proteins from 80 aliquots of MGS
were pooled and subjected to further study.
Structural analysis
Amino acid sequences of the N-terminus and partial interior
peptide fragments recovered from trypsin hydrolysis were
determined by automated Edman degradation on an Applied
Biosystems pulsed liquid-phase sequencer, model 491.
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
analysis and protein concentration determination
SDS-PAGE was performed under reduced and/or un-reduced
conditions. Protein samples were loaded onto a 15% polyacryl-
amide gel. Protein bands were observed after using a standard
Comassie blue stain. The protein concentration was determined
by a protein assay kit (Bio-Rad, Hercules, CA) with bovine serum
albumin as a standard.
cDNA library construction,cDNA screening and
phylogenetic tree construction
Total RNA was extracted using TRIzol (Life Technologies,
Ltd.) from 60 mid-guts of E. sinensis. cDNA was synthesized by
SMART
TM techniques by using a SMART
TM PCR cDNA
synthesis kit (Clontech, Palo Alto, CA) according to the
manufacturer instructions. A directional cDNA library was
constructed with a plasmid cloning kit (SuperScript
TM Plasmid
System, GIBCO/BRL) following the instructions of manufacturer,
producing a library of about 5.7610
5 independent colonies. PCR-
based method for high stringency screening of DNA libraries was
used for screening and isolating clones. The specific primers in the
sense direction as listed in Table S1 designed according to the
peptide fragment sequences of determined by Edman degradation
and primer IIA (59-AAGCAGTGGTATCAACGCAGAGT-39)
provided by the SMART
TM PCR cDNA synthesis kit in the
antisense direction were used in PCR reactions. The DNA
polymerase was Advantage polymerase from Clontech (Palo Alto,
CA). The PCR conditions were: 2 min at 94uC, followed by 30
cycles of 10 sec at 92uC, 30 sec at 53uC, 40 sec at 72uC. DNA
sequencing was performed on an Applied Biosystems DNA
sequencer, model ABI PRISM 377.
Totally twenty insect serine protease sequences were obtained
from the protein database at the National Center for Biotechnol-
ogy Information. Multiple sequence alignments were constructed
by using the ClustalW program (version 1.8) on basis of the whole
recursor of these serine proteases. The phylogenetic trees were
constructed using neighbor-joining method (MEGA4.0), by
calculating the proportion of amino acid differences (p-distance)
among all sequences. A total of 500 bootstrap replicates were used
to test the reliability of each branch. The numbers on the branches
indicate the percentage of 500 bootstrap samples supporting the
branch.
Recombinant expression of eupolytin1
The coding region including restriction enzyme sites for
eupolytin1 was isolated from the cDNA library. Two PCRs were
performed to insert enzymatic processing sites for enterokinase,
HindIII and KPN1 The primer pair for the first PCR to introduce
enzymatic processing sites for enterokinase and HindIII is 59-
BD1810-1: 59-GATGATGACAAGATTGTTGGAGGTT-39
and 39-BD1810-1: 59-CCCCCAAGCTTCTAGTTGACTC-
CAG-39. The primer pair for the second PCR to introduce
enzymatic processing site for KPN1 is 59-BD1810-2: 59-
CGGGGTACCGATGATGATGACAAG-39 and 39-BD1810-1.
PCRs were performed by running 30 cycles with a temperature
profile of 30 s at 95uC, 30 s at 57uC, and 60 s at 72uC. The
purified PCR product was digested with HindIII and KPN1, and
Figure 6. Assays of plasminogen activation and fibrinolysis of
eupolytin1. (A) 5 ml plasminogen (11.2 mM); (B) 5 ml eupolytin 1
(3.5 mM); (C) 5 ml eupolytin 1 (3.5 mM) incubated with 5 ml plasminogen
(11.2 mM); (D) 5 ml urokinase (3.5 mM) incubated with 5 ml plasminogen
(11.2 mM). E: eupolytin1; U: urokinase; P: plasminogen.
doi:10.1371/journal.pone.0017519.g006
Table 1. Kinetic parameters of eupolytin1 for different
chromogenic substrates.
T6140 B3133
NE RE NE RE
Km (mM) 20.17 20.02 3.24 3.01
Vmax (mM.S
21) 2.47 2.39 1.05 1.12
Kcat (10
5 S
21) 2.10 2.25 0.32 0.29
Kcat/Km (10
5 mM
21 S
21) 0.10 0.11 0.10 0.08
These data represent mean values of three independent experiments. NE:
native eupolytin1; RE: Recombinant eupolytin1.
doi:10.1371/journal.pone.0017519.t001
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restriction sites. Expression, purification and refolding of the
recombinant His-tagged protein were performed according to the
manufacturer’s instruction (Novagen). Recombinant protein was
released by enterokinase from the fusion protein. It was purified
from the digestive mixture by AKTA FPLC Mono Q anionic
exchange column as mentioned above (Fig. S1).
Serine protease and fibrinogenolytic assays
Serine protease and fibrinogenolytic assays of the native purified
protein were carried out according to our previous method [8,9].
The hydrolysis of synthetic chromogenic substrates by the tested
samples was assayed in 50 mM Tris–HCl, pH 7.8 at 37uC. The
substrates are T6140 (N-(p-Tosyl)-Gly-Pro-Lys 4-nitroanilide
acetate salt, Sigma) and B-3133 (N-Benzoyl-Arg-4-nitroanilide-
hydrochride-pNA, Sigma). The reaction was initiated by the
addition of the substrate to a final concentration of 0.5 mM. The
formation of p-nitroaniline was monitored continuously at 405 nm
for 5 min. 1 ml 20 mg/ml bovine fibrinogen was incubated with
the tested samples in 25 ml 50 mM Tris-HCl, pH 7.6 containing
150 mM NaCl at 37uC for different times, and then subjected to
reduced SDS-PAGE analysis on a gel with a concentration of
12%. The inhibition on platelet aggregation was determined
according to previous method [9]. Platelet aggregation was
monitored by light transmission in an aggregometer (Plisen,
Beijing) with continuous stirring at 37uC.
In vitro clot lysis with human blood
Clots were formed by adding thrombin and excess calcium into
health human whole blood. After 90 min incubation at 37uC, the
retracted clots were packed into 5-cm sections. Test samples
(native protein) were administered into the clots and the lysis was
visually monitored. All the human experiments are approved by
Kunming Institute of Zoology, Chinese Academy of Sciences. The
informed consent from all participants involved in your study was
obtained in written, and the consent procedure was also approved
by Kunming Institute of Zoology, Chinese Academy of Sciences.
Plasminogen activation and fibrinolysis assay
A fibrin plate lysis assay was conducted in a 12-well plate. A
mixture consisting of 1 ml of fibrinogen (5 mg/ml), 1 ml of 1%
agarose solution and thrombin (1 unit) in 20 mM Tris–HCl buffer,
Figure 7. Anti-thrombosis activities of eupolytin1 in vivo. A: Effects of eupolytin1 and urokinase on thrombus formation induced by contact
activation in rat arteriovenous shunt models; B: Effects of eupolytin1 and urokinase on thrombus formation induced by carrageenan in mouse tail. EN:
eupolytin1. * P,0.05 and ** P,0.01 from saline control.
doi:10.1371/journal.pone.0017519.g007
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1 h incubation at room temperature, the native sample was placed
on the surface and incubated overnight at 37uC. The diameter of
the lysed areas was measured. Plasminogen (with no plasmin) and
urokinase were used as negative and positive control, respectively.
In the fibrinolysis assay, the drug aprotinin (Sigma, A4529, 1, 2,
4 mg), which inhibits trypsin and related proteolytic enzymes, was
mixed with 1 mg eupolytin1 sample, and incubated with 20 mg
fibrinogen in order to eliminate the interference of plasmin, which
would be produced by eupolytin1 activation if there was
plasminogen contaminated in the sample.
Anti-thrombosis study by rat arteriovenous shunt
thrombosis model
Male Wistar rats (180–220 g) were used for rat arteriovenous
shunt thrombosis model according the method described by
Sperzel and Huetter [18]. Rats were anesthetized by intraperito-
Figure 8. Hemostatic evaluation induced by urokinase (A) and eupolytin1 administration in mice (B). (C) Fibrinogen concentration
change induced by urokinase and eupolytin1 administrations in mice. EN: eupolytin1.
doi:10.1371/journal.pone.0017519.g008
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(15 mg kg). The left jugular vein and right common carotid artery
were isolated and catheterized by a shunt catheter (American
Health & Medical Supply International Corp. Co., Ltd). This
catheter is composed of three parts including two 100-mm-long
polyethylene (PE)-60 catheters, which were introduced into the
blood vessels, and a 30-mm-long PE-160 catheter that is in the
middle of the two PE-60 catheters. A rough nylon thread (60 mm
in length and 0.26 mm in diameter) folded into a double string was
in the middle PE-160 catheter to induce thrombosis. For sample
administration, a saline-filled PE-60 catheter was cannulated to
the exposed femoral vein. Different dose of samples (n=9 per
dose) were administered through the PE-60 catheter cannulated to
the femoral vein. After 15 min administration of sample, the shunt
was opened for 5 min, and then closed. Nylon strings were
removed from the middle PE-160 catheter; the wet thrombi
attached in the nylon strings were weighed. All the experimental
protocols of animal models were approved by the Animal Care
and Use Committee at Kunming Institute of Zoology, Chinese
Academy of Sciences. The approval ID for this study was
syxk2009-0007.
Anti-thrombosis study by carrageenan-induced mouse
tail thrombosis model
Carrageenan-induced mouse tail thrombosis model was used to
evaluate antithrombosis in vivo. The general procedures were the
same as those in previous reports [19]. The tested sample was
injected into mice by caudal vein. After 30 min of the injection,
1% k-Carrageenan dissolved 0.9% NaCl was intraperitoneally
injected into mice to induce thrombosis in tails. The tested sample
was injected into mice by caudal vein again after 6 h of the
carrageenin injection. The length of thrombus in tails of mice was
measured after 48 h treatment.
Fibrinolytic hemorrhage assay in vivo
According to previous reports, rabbit ear-puncture technique
was used to assess fibrinolytic hemorrhage [20–22]. Primary
bleeding times (PBT) were performed before, during and after
agent infusion, and all lesions were monitored for re-bleeding.
Blood samples were collected on citrate anticoagulant (0.5 ml,
0.25 M sodium citrate). After centrifugation at 3000 g at 4uC for
30 min to obtain platelet-poor plasma and tested immediately for
fibrinogen concentration.
All the experimental protocols of animal models were approved
by the Animal Care and Use Committee at Kunming Institute of
Zoology, Chinese Academy of Sciences.
Statistics
Data were analyzed by X
2 and by t test or repeated measure
analysis of variance (ANOVA) comparison of means.
Supporting Information
Figure S1 SDS-PAGE of fractions from the purification
of recombinant eupolytin1. Lane 1: un-induced cells. Lane 2:
induced cell. Lane 3:purified fusion protein after affinity
chromatography. Lane 4: purified protein after enterkinase
cleavage. Lane 5: purified protein after Mono-Q FPLC. Lane 6:
protein marker.
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Table S1 Primers for cDNA clone screening of eupolytin 1.
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